Precigen, Inc. (NASDAQ:PGEN) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET

Company Participants

Steve Harasym - Vice President, Investor Relations

Helen Sabzevari - President & Chief Executive Officer

Harry Thomasian - Chief Financial Officer

Conference Call Participants

Jason Butler - JMP Securities

Ben Burnett - Stifel

Arthur He - H.C. Wainwright

Jennifer Kim - Cantor Fitzgerald

Operator

Good day, and welcome to the Precigen Third Quarter 2022 Financial Results Conference Call. Today, all participants will be in a listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note that today's event is being recorded.

I would now like to turn the conference over to Steve Harasym, Vice President of Investor Relations. Please go ahead.

Steve Harasym

Thank you, operator, and thank you for joining us today. With me are Dr. Helen Sabzevari, President and CEO; and Harry Thomasian, CFO of Precigen.

Helen will provide an update on the significant progress we have made across our pipeline programs and highlight our anticipated upcoming milestones. After which Harry will review our third quarter 2022 financial results. Following our prepared remarks, we will open the call to Q&A.

Before we begin, please note that during today's call, we will make various forward-looking statements. Investors are cautioned that such forward-looking statements are based on current expectations and are subject to risks and uncertainties that could actual -- that could cause actual results to differ from those indicated by our forward-looking statements. Please read the Safe Harbor statement in the press release as well as risk factors contained in Precigen's most recent SEC filings for a more complete discussion of these risks and uncertainties.

I will now turn the call to Dr. Sabzevari. Helen?

Helen Sabzevari

Thanks, Steve, and thank you for joining us today. I'm pleased to report to you today that Precigen made significant progress during the third quarter of 2022, while focusing on the assets in our portfolio offering the greatest potential for increasing shareholder value in the most efficient way possible.

Focus is on mantra here at Precigen, and our strategy is straightforward. First, we focus on markets with ultra high unmet need. The indication we are pursuing offer the potential for an accelerated regulatory and developmental pathway.

Second, we continue focusing our research, development and manufacturing operations by making early decisions to pursue therapies with higher probabilities of success. The ability to create consistent manufacturing at multiple sites also figures into our decision-making as we seek to decrease product costs and provide therapeutic access to a broader patient population. We need to move away from traditional concepts of centralized manufacturing, especially when we are dealing with patient population suffering from diseases where earlier treatment makes a big difference.